Adjuvant therapy with high dose vitamin D following primary treatment of melanoma at high risk of recurrence: a placebo controlled randomised phase II trial (ANZMTG 02.09 Mel-D)
Open accessThe DOI matches its Crossref record; 5 of the 5 references it cites were found in a registry or an index.
Abstract
BACKGROUND: Patients with primary cutaneous melanomas that are ulcerated and >2 mm in thickness, >4 mm in thickness and those with nodal micrometastases at diagnosis, have few options for adjuvant treatment. Recent studies have suggested a role for vitamin D to delay melanoma recurrence and improve overall prognosis. METHODS/DESIGN: This is a pilot placebo-controlled randomised phase II trial to assess the feasibility, safety and toxicity of an oral loading dose of Vitamin D (500,000 IU) followed by an oral dose of 50,000 IU of Vitamin D monthly for 2 years in patients who have been treated for cutaneous melanoma by wide excision of the primary. Patients aged 18-79 years who have completed primary surgical treatment and have Stage IIb, IIc, IIIa (N1a, N2a) or IIIb (N1a, N2a) disease are eligible for randomisation 2:1 to active treatment or placebo. The primary endpoints are sufficiency of dose, adherence to study medication and safety of the drug. The secondary endpoints are participation and progression free survival. The study has been approved by the Ethics Review Committee (RPAH Zone) of the Sydney Local Health District, protocol number X09-0138. DISCUSSION: Effective, non-toxic adjuvant therapy for high risk primary melanoma is not currently available. Favorable outcomes of this phase II study will form the basis for a multi-centre phase III study to assess whether the addition of oral high-dose vitamin D therapy in patients who have completed primary treatment for melanoma and are at high risk of recurrence will: 1. prolong time to recurrence within 5 years 2. improve overall survival at 5 years and 3. be both safe and tolerable. 62 patients have been randomised since the study commenced in December 2010. Target accrual for the study has been met with 75 patients randomised between December 2010 and August 2014.The Mel-D trial is conducted by the Australia and New Zealand Melanoma Trials Group (ANZMTG 02.09) TRIAL REGISTRATION: Australia and New Zealand Clinical Trials Registry (ANZCTR) ACTRN12609000351213.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Autier, P. (2007) · Archives of Internal Medicine · doi:10.1001/archinte.167.16.1730 · Cited by 1,104
Newton-Bishop, J. A., Beswick, S., Randerson-Moor, J., Chang, Y.-M., Affleck, P., Elliott, F., Chan, M., Leake, S., Karpavicius, B., Haynes, S., et al. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2009.22.1135 · Cited by 295 · cited 2×
“Furthermore, in observational studies of patients with melanoma, low 25OHD was associated with worse outcomes [34] and low 25OHD at the time of diagnosis was associated with an increased risk of progression and death over the subsequent 5 years [33].”
BackgroundExpression of vitamin D receptor decreases during progression of pigmented skin lesions
Brożyna, A. A., Jozwicki, W., Janjetovic, Z., & Slominski, A. T. (2011) · Human Pathology · doi:10.1016/j.humpath.2010.09.014 · Cited by 120
Tang, J. Y., Fu, T., LeBlanc, E., Manson, J. E., Feldman, D., Linos, E., Vitolins, M. Z., Zeitouni, N. C., Larson, J., & Stefanick, M. L. (2011) · Journal of Clinical Oncology · doi:10.1200/jco.2011.34.5967 · Cited by 117 · cited 1×
“38) [30].”
Brożyna, A. A., Jóźwicki, W., Janjetovic, Z., & Slominski, A. T. (2013) · Human Pathology · doi:10.1016/j.humpath.2012.03.031 · Cited by 70
Cited by
Slominski, A. T., Brożyna, A. A., Zmijewski, M. A., Jóźwicki, W., Jetten, A. M., Mason, R. S., Tuckey, R. C., & Elmets, C. A. (2017) · Laboratory Investigation · doi:10.1038/labinvest.2017.3 · Cited by 136
Self-citationNoncalcemic 20-hydroxyvitamin D3 inhibits human melanoma growth in in vitro and in vivo models
Skobowiat, C., Oak, A. S. W., Kim, T.-K., Yang, C. H., Pfeffer, L. M., Tuckey, R. C., & Slominski, A. T. (2017) · Oncotarget · doi:10.18632/oncotarget.14193 · Cited by 44
“The anticancer properties of D3 [14, 33, 35, 36] served as the rationale for an ongoing phase II clinical trial in Australia evaluating the use of vitamin D as an adjuvant therapy for treating melanoma with a high risk of recurrence [37].”
BackgroundRusso, I., Caroppo, F., & Alaibac, M. (2015) · Cancers · doi:10.3390/cancers7030841 · Cited by 29
“Recently, a placebo-controlled randomised phase II trial was started to evaluate the safety and toxicity of oral vitamin D in patients who have completed primary surgical treatment of melanoma [69].”
Background
Metadata
- Authors
- Saw, R. P., Armstrong, B. K., Mason, R. S., Morton, R. L., Shannon, K. F., Spillane, A. J., Stretch, J. R., & Thompson, J. F.
- Venue
- BMC Cancer
- Published
- 2014-10-24
- Volume
- 14
- Issue
- 1
- Pages
- 780-780
- ISSN
- 1471-2407 (ISSN-L)
- OpenAlex
- W2126101222
- Cited by
- 39
- References
- 5
- FWCI
- 2.30
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Adjuvant therapy with high dose vitamin D following primary treatment of melanoma at high risk of recurrence: a placebo controlled randomised phase II trial (ANZMTG 02.09 Mel-D). https://app.cochat.ai/papers/10.1186/1471-2407-14-780
- The paper
- Saw, R. P., Armstrong, B. K., Mason, R. S., Morton, R. L., Shannon, K. F., Spillane, A. J., Stretch, J. R., & Thompson, J. F. (2014). Adjuvant therapy with high dose vitamin D following primary treatment of melanoma at high risk of recurrence: a placebo controlled randomised phase II trial (ANZMTG 02.09 Mel-D). BMC Cancer. https://doi.org/10.1186/1471-2407-14-780
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.